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Abstract
Background: Natalizumab provides rapid and high-efficacy control of multiple sclerosis disease activity with long-
term stabilization. However, the benefits of the drug are countered by a risk of developing progressive multifocal
leukoencephalopathy in patients infected with the John Cunningham Virus. Close monitoring is required in patients
with increased progressive multifocal leukoencephalopathy risk receiving natalizumab in the long-term for an
optimal benefit-risk evaluation. Standardized high-quality monitoring procedures may provide a superior basis for
individual benefit and risk evaluation and thus improve treatment decisions. The non-interventional study TRUST
was designed to capture natalizumab effectiveness under real-life conditions and to examine alternate approaches
for clinical assessments, magnetic resonance imaging monitoring and use of biomarkers for progressive multifocal
leukoencephalopathy risk stratification.
Methods/Design: TRUST is a non-interventional, multicenter, prospective cohort study conducted at approximately
200 German neurological centers. The study is intended to enroll 1260 relapsing-remitting multiple sclerosis
patients with ongoing natalizumab therapy for at least 12 months. Patients will be followed for a period of 3 years,
irrespective of treatment changes after study start. Data on clinical, subclinical and patient-centric outcomes will be
documented in order to compare the effectiveness of continuous versus discontinued natalizumab treatment.
Furthermore, the type and frequency of clinical, magnetic resonance imaging and biomarker assessments, reasons
for continuation or discontinuation of therapy and the safety profile of natalizumab will be collected to explore the
impact of a systematic patient management approach and its potential impact on patient outcome. Specifically, the
role of biomarkers, the use of expert opinions, the impact of high-frequency magnetic resonance imaging
assessment for early progressive multifocal leukoencephalopathy detection and the role of additional radiological
and clinical expert advice will be explored.
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Discussion: TRUST was initiated in spring 2014 and enrollment is anticipated to be completed by mid 2016. Annual
interim analyses will deliver continuous information and transparency with regard to the patient cohorts and the
completeness and quality of data as well as closely monitor any safety signals in the natalizumab-treated cohort.
The study’s results may provide insights into opportunities to improve the benefit-risk assessment in clinical practice
and support treatment decisions.
Keywords: Natalizumab, Relapsing-remitting multiple sclerosis, Progressive multifocal leukoencephalopathy, John
Cunningham virus
Background
Natalizumab (Tysabri®) is an intravenous humanized mono-
clonal antibody directed against α4-integrin (CD49d), a
specific adhesion molecule located on the surface of lym-
phocytes and other immune cells. The binding of natalizu-
mab to its target inhibits the transmigration of lymphocytes
across the blood-brain barrier, leading to reduced
disease activity in relapsing-remitting multiple sclerosis
(RRMS) [1].
The efficacy of natalizumab in RRMS was demonstrated
in a randomized, double-blind, placebo-controlled 2-year
trial. At 2 years, natalizumab reduced the risk of sustained
disease progression, as measured by the Expanded Disabil-
ity Status Scale (EDSS), by 42 %. The annualized relapse
rate (ARR) was diminished by 68 %, and the number of
new or newly enlarging T2-weighted (T2w) lesions and the
number of gadolinium-enhancing lesions on T1-weighted
MRI were significantly lower compared to placebo (83 and
92 %, respectively) [2].
Natalizumab was reintroduced in 2006 by the Food
and Drug Administration (FDA) and first licensed by the
European Medicines Agency (EMA) in 2006, substan-
tially improving treatment options in RRMS patients
with poorly controlled disease activity [3]. Long-term
data, including clinical observations for up to 5 years of
treatment with natalizumab, confirm its sustained effect
on disease activity [4]. A retrospective matched-paired
analysis strongly suggested natalizumab’s superior effi-
cacy over fingolimod [5]. The greatest observed benefit
of natalizumab has been as first-line MS therapy in
patients with EDSS values <3 and lower relapse rates at
the start of therapy.
To date, more than 149,000 patients have been
treated with natalizumab. Natalizumab’s generally fa-
vorable safety profile is based on more than 475,000
patient-years of drug exposure [6, 7]. However, the risk
of developing progressive multifocal leukoencephalo-
pathy (PML), an often severely disabling disease, limits
Fig. 1 Overview of data documented in TRUST. (S)AE = (serious) adverse event
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the use of natalizumab, and a careful benefit-risk as-
sessment for each patient must be continuously per-
formed by the treating physician. PML had been
reported most prominently in HIV patients and
emerged in MS patients after natalizumab was first in-
troduced in 2004 [8–10]. Sporadic cases of PML have
also been reported in MS patients receiving fingolimod
or dimethyl fumarate irrespective of pretreatment with
natalizumab [11, 12].
The causative agent of PML is the John Cunningham
virus (JCV). The risk of developing PML is significantly
increased in natalizumab-treated patients who (i) are
anti-JCV antibody seropositive, (ii) have received natali-
zumab treatment for 2 or more years and (iii) have been
exposed previously to immunosuppressants [13]. Re-
cently, the correlation of PML-Risk and the JCV-Index
has been proven as an additional risk factor in patients
without previous immunosuppressive treatment (14),
which has led to new recommendations of the European
medical regulatory authority [14] Some anti-JCV–sero-
negative patients demonstrate fluctuating antibody status
over time, and the risk of PML in these patients is un-
clear, although most seroconverters appear to have low
levels of anti-JCV antibodies [15].
Recent studies on immunological biomarkers indicate
that some of them could be used to further stratify the risk
of PML in patients treated with natalizumab [16]. The
JCV antibody index is determined by comparing the levels
of antibodies of a specific patient to a reference cohort.
Analyses from anti-JCV antibodies positive patients with
no prior IS treatment suggests that lower index values are
associated with a lower risk of developing PML [17].
Measuring L-selectin expression on cryopreserved
CD4+ T cells as well as soluble L-selectin in plasma has
gained attention lately [17, 18]. However, its usage in
clinical practice is hampered by difficulties in sample
handling, leading to problems in obtaining consistent re-
sults, and is not reliable for assessing PML risk [18–20].
Initial data suggest that the presence of oligoclonal lipid-
specific IgM in CSF may be associated with a lower
PML risk [21]. In addition, research demonstrating the
down regulation of CD49 and CD29 on CD4+ and CD8+
T cells, as well as CD11a and CXCR3, reveals the impact
of natalizumab treatment on a variety of cell membrane
markers. However, all these novel biomarkers have yet to
be validated in the clinical setting [18].
Currently, the diagnosis of PML is based on clinical
symptoms, typical PML lesions detected by MRI and the
presence of JCV DNA in cerebrospinal fluid and/or biopsy
of brain tissue [22]. Published studies indicate that the
detection of PML at an early, asymptomatic stage is associ-
ated with a better prognosis [23]. Therefore, high-sensitivity
quantitative polymerase chain reaction testing should be
performed by qualified laboratories if PML is suspected
[22]. In addition, MRI protocols such as high-frequency
MR monitoring with adjusted sequences and image evalu-
ation by experienced radiologists have been suggested to fa-
cilitate the detection of PML (Table 1) [24].
Real-life patient management, PML risk stratification
using biomarkers and early detection of PML via MRI
monitoring and clinical screening are handled in a
variety of ways. Furthermore, natalizumab treatment is
often discontinued due to reasons other than break-
through disease, and a return of disease activity to baseline
Fig. 2 Electronic patient data documentation and management in TRUST. Patient data are captured electronically by the Multiple Sclerosis
Documentation System (MSDS3D). A specific module of the software has been created for the TRUST study, allowing for electronic entry of
pseudonymized visit data and patient questionnaire data. The clinical database and the MSDS3D TRUST software were developed by the MSDS3D
Project Group at the Neurological Clinic of the Technical University Dresden, Germany, which is also responsible for data management. Integrated
functions in MSDS3D-TRUST System include: Visual display of history, events and course of disease, Direct access to requests of neurological expert
advice and neuroradiological second opinion, Pseudonymized and individual patient data access for clinical and radiological experts,
Straightforward clinical data monitoring for compilation of robust and high-quality results
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levels is observed in most patients [25–27]. Long-term,
well-structured patient monitoring is thus required to en-
able individualized treatment approaches and decisions
[28]. McGuigan et al. recently proposed consensus expert
guidance for in-practice risk management [29], and tools
simplifying the implementation of such approaches, such
as the multidimensional Multiple Sclerosis Documenta-
tion System (MSDS3D), are increasingly being used to
monitor MS patients [30]. More widespread use of the
available instruments may benefit patients treated with
natalizumab. However, little is known about the utility of
risk-adapted diagnostics and their use for monitoring and
treatment decision making in the routine clinical setting.
Management of MS patients in Germany is highly
heterogeneous. Treating physicians have diverse back-
grounds–varying from academians at institutions with
international reputations in the field of MS to office-based
neurologists with a minor focus on MS. Many neurologists
treating MS patients are organized in regional networks.
This allows them to obtain advice (e.g., from academic insti-
tutions) for individual patient care. Therefore, the use of
expert opinions as an additional element to aid in decision
making, with respect to management of natalizumab-treated
patients, may be another significant aspect of routine care.
In routine settings, natalizumab is frequently discon-
tinued in patients with two of the established risk factors
(anti-JCV antibody positive and at least 2 years of natali-
zumab therapy) without performing an individualized
benefit-risk assessment, thus potentially exposing these
patients to a heightened risk of MS relapses and acceler-
ated disease progression [27, 31]. To date, the conse-
quences of a treatment change following natalizumab
discontinuation have been examined only in smaller
studies, with a limited number of centers involved and
follow-up duration. There is, therefore, a need to better
understand the reasons for treatment change and its
merits and disadvantages under real-life circumstances.
Furthermore, JCV-positive patients switching from nata-
lizumab to dimethyl fumarate or fingolimod are not to-
tally safe in regard to contracting PML.
The non-interventional study TRUST (TysabRi® pa-
tient management via a longitUdinal multidimensional
STudy) was designed primarily to capture the real-life
efficacy of natalizumab in patients on long-term therapy
but also to understand the range of approaches to PML
risk stratification via clinical assessments, MRI monitor-
ing and use of candidate biomarkers and expert advice,
and the utility of adaptive integrated management tools.
The results may provide insights to improve the benefit-
risk assessment in clinical practice and support treat-
ment decisions.
In this article we report the design, methods and pro-
cedures of this study.
Methods/Design
Study goals and scope
The major study goals of TRUST are (i) to assess the
course of disease over 36 months in patients with sus-
tained natalizumab therapy versus those who discontinue
natalizumab treatment; (ii) to evaluate the use and effects
of an integrated adaptive patient management approach,
including multimodal monitoring and utilization of expert
advice; (iii) to assess the factors affecting the decision to
continue or discontinue natalizumab treatment; (iv) to
explore patient-centric outcomes in patients continuing
versus discontinuing natalizumab treatment.
TRUST includes patients with RRMS treated with natali-
zumab for at least 12 months, regardless of their duration
of disease. The study will collect information that is rou-
tinely acquired in clinical practice in Germany. Patients
Table 1 MAGNIMS consensus guideline: regimens for risk-based MRI monitoring in MS patients treated with natalizumab [24]
Population Recommended MRI regimen Interval
Natalizumab-treated patients
at high risk of PML (ie, anti-JCV seropositive
AND treatment duration ≥18 months)
• Conventional T2-weighted imaging
• T2-FLAIR
• DWI
• Contrast-enhanced T1-weighted imaging
[in patients with suspected PML lesions]
• Every 3–4 months
Natalizumab-treated patients at low risk of PML
(i.e., anti-JCV seronegative)
• Conventional T2-weighted imaging
• T2-FLAIR
• DWI
• Every 12 months
Patients who switch from natalizumab to other drugs
(including fingolimod, alemtuzumab, dimethyl fumarate)
• Conventional T2-weighted imaging
• Contrast-enhanced T1-weighted imaging
• Every 3–4 months, for
up to 12 months
Patients at high risk of developing opportunistic
infections who are switching immunotherapies
• Conventional T2-weighted Imaging
• Contrast-enhanced T1-weighted imaging
• T2-FLAIR
• DWI
• Contrast-enhanced T1-weighted imaging
[in patients with suspected PML lesions]
• At end of ongoing
therapy
• After starting therapy
with the next drug
DWI diffusion-weighted imaging, FLAIR fluid-attenuated inversion recovery
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will be followed for 3 years, irrespective of whether natali-
zumab treatment is continued or discontinued, providing
information to assess the efficacy of natalizumab in a
real-life setting (Fig. 1). Furthermore, factors influen-
cing the decision to continue or discontinue natalizu-
mab will be documented. Lastly, TRUST will evaluate
the utility of integrated adaptive patient management
approaches for monitoring patients with RRMS with re-
spect to disease activity, discontinuation of therapy and
patient safety.
The non-interventional observational prospective study
design allows the exploration of the use of PML risk-related
biomarkers such anti-JCV-Antibody status and - Index in
Serum [15] as well as the utility of newer, non-validated
biomarkers, such as JCV-Antibody index in serum/CSF
[32] and lipid specific IgM bands [21] in treatment deci-
sions and of MRI for early detection of PML in a real-world
setting. Furthermore, patient-centric outcomes will be cap-
tured in order to understand the impact of different treat-
ment alternatives on the patients’ daily situation.
Study population and sample size
TRUST will include a total of 1260 patients from ap-
proximately 200 centers in Germany who fulfill the fol-
lowing criteria: at least 18 years of age at inclusion;
diagnosis of RRMS according to McDonald criteria
(2010 version) [33]; treatment with natalizumab accord-
ing to prescription information for at least 12 months
and informed consent prior to participating in the study.
Patients with any of the following characteristics will
be excluded from the study: progressive forms of MS;
participation in the non-interventional Tysabri Observa-
tional Program (TOP) [3] (patients included in the German
REGIMS registry [34] may participate); simultaneous ther-
apy with another drug indicated for the treatment of RRMS
or contraindications to natalizumab treatment according to
prescription information.
Patient recruitment in TRUST was initiated in August
2014. The planned duration for recruitment is 22 months.
Currently, approximately 170 neurologists, 120 radiologists
and 1000 patients are participating in the study. The geo-
graphic distribution of centers throughout Germany follows
the population density. About two-thirds of the centers are
office-based neurologists and one-third are hospitals, in-
cluding eight large academic institutions. The planned dur-
ation of observation period per patient is 36 months. Data
acquisition is expected to be completed in 2019.
Due to the study design, a high level of drop out is
expected. Hence, assuming a Poisson distribution and
3 years of follow-up,1260 patients will be included in
the study to adjust for study dropouts and patients
restarting natalizumab treatment in order to detect dif-
ferences with an alpha level of 0.05.
Procedures
Data are acquired using the MS patient management
and documentation software package MSDS3D. A spe-
cific module of the MSDS3D software platform was
developed for TRUST that can be used either as a local
application or as an online web interface (Fig. 2). The
MSDS3D is currently used for the documentation in the
REGIMS registry of the Competence Network Multiple
Sclerosis (KKNMS) and the German MS Society (DMSG)
Registry.
Patient data are documented using electronic report-
ing forms. Patient-centric outcomes are entered in
questionnaires.
Neurologists who make use of clinical expert advice at
any time during the study and radiologists seeking an
MRI second opinion reading are asked to document
such processes.
Study procedures are intended explicitly to not inter-
fere with or exert influence on therapeutic decisions
made by the treating neurologist.
Data acquisition
Data and measurements recorded in TRUST are listed in
Table 2. Patient data are recorded at study entry (baseline/
visit #1) and at 12 subsequent visits (visit #2 through #13,
conducted approximately every 3 months until month 36
after baseline). Visits and measurements are performed
within the framework of routine clinical care without
causing any additional burden to the patient.
Patient-related data are exclusively recorded and proc-
essed in pseudonymized formats. The clinical database is
managed by the Center of Clinical Neuroscience, University
of Dresden, the imaging database in a joint project by med-
iri GmbH and the University Goettingen (JW). Electronic
data transfer to the TRUST study server is SSL encrypted.
National data privacy laws apply to all data processing.
Ongoing documentation independent of visit dates
includes changes/interruptions in natalizumab or other
MS therapy, changes in co-medications, reporting of
adverse events (AEs) and pregnancies and utilization of
expert advice.
Patient-centric outcomes
Patient-centric outcomes are captured through the follow-
ing six instruments: treatment satisfaction (Treatment
Satisfaction Questionnaire for Medication [TSQM-9]), fa-
tigue (Fatigue Scale for Motor and Cognitive Functions
[FSMC]), MS-related quality of life (Multiple Sclerosis Im-
pact Scale-29 items [MSIS-29]), depression (Hospital Anx-
iety and Depression Scale [HADS]), cognitive function
(Symbol Digit Modality Test [SDMT]) and work productiv-
ity/activity (Work Productivity and Activity Impairment
Questionnaire [WPAI]). Questionnaires are administered at
baseline and every 6 months during follow-up. Patients fill
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in the questionnaires using tablet computers or in paper-
and-pencil format with the exception of the SDMT, which
is administered by the site staff as a paper-based test. All
data are transferred into the TRUST database either
directly from the tablet or after digitalization from paper-
based entries.
Documentation at end of follow-up
At the end of follow-up, i.e. at the end of study partici-
pation, reasons for premature study discontinuation (if
applicable), discontinuation or continuation of natalizu-
mab, type of next therapy and patient questionnaire
entries are recorded.
Adverse events
An AE is defined as any unfavorable change in the pa-
tient’s pretreatment condition, regardless of a potential
relation to treatment and irrespective of whether the
medication was used as prescribed. AEs are reported in-
dependently from the planned study visits using an AE
report form in the TRUST module of MSDS3D-TRUST.
Serious adverse events (SAEs) include lethal or life-
threatening events, hospitalizations, events leading to
major incapacity, persistent or significant disability, con-
genital anomaly or birth defects and events that are
otherwise medically significant. Abnormal laboratory
values and test results may also be considered SAEs.
SAEs must be reported within 24 h after their recogni-
tion to the manufacturer of natalizumab. In cases where
indications of suspected PML is revealed within the
frame of the optional clinical or imaging expert advice
process, treating neurologists and (neuro-)radiologists
are notified within 24 h.
Documentation of expert advice utilization
Clinical expert advice If a clinical opinion from an ex-
pert neurologist or radiologist is requested, the requesting
physician is asked to document his or her satisfaction with
the timing and content of the advice.
Imaging expert advice Neuroradiological centers may
optionally request an MRI expert advice second opinion
as part of the clinical routine. For this purpose, anon-
ymized patient data is transferred per DICOM (Digital
Imaging and Communications in Medicine) to a data-
base separate from the clinical database. Patient identifi-
cation and data quality checks are performed prior to
image reading according to a prespecified protocol. The
MRI database and MRI quality assurance processes used
in TRUST have been developed by the University of
Göttingen in cooperation with the Medical Imaging Re-
search Institute (mediri), which is responsible for MRI













History (medical, MS): x
First MS diagnosis
Other underlying diseases




MRI status at baseline
Opportunistic infections before




Status of current treatment x
Current EDSS score x x
Relapse(s) since last visit
(number, date)
x
AE at/since (last) visit (yes, no) x continuously
Anti-JCV serostatus x




Resources used (nurse contact,
other HCP, clinic)
x








x every 12 months
FSMC (fatigue) x every 12 months
MSIS-29 (MS-related
quality of life)
x every 12 months
HADS (depression) x every 6 months
SDMT (cognitive function) x every 6 months
WPAI (productivity) x every 6 months
Expert advice requested if available
MRI results x if available
Due to the non-interventional character of the study, only data collected
within the routine clinical practice are documented
TSQM-9 Treatment Satisfaction Questionnaire for Medication, FSMC Fatigue
Scale for Motor and Cognitive Functions, MSIS-29 Multiple Sclerosis Impact
Scale-29 items, HADS Hospital Anxiety and Depression Scale, SDMT Symbol
Digit Modality Test, WPAI Work Productivity and Activity
Impairment Questionnaire
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data management and the optional MRI second opinion
reading process.
Quality control
Quality control in TRUST aims at ensuring a complete
dataset as detailed in the recommendations for planning,
conduct and analysis of non-interventional observational
studies issued by the German Federal Institute for Drugs
and Medical Devices [35]. Plausibility and completeness
of data are checked during entry. Missing information
and discrepancies are clarified via queries to the individ-
ual study center according to a predefined data valid-
ation plan. The conduct of the study is supervised by
monitors of the contract research organization according
to a predefined monitoring plan. The data management
center examines the data transferred from the centers
for potential unreported adverse events.
Reporting and data analyses
On completion of documentation, all recorded data will
be analyzed using descriptive statistics according to the
recommendations for observational studies [36]. Yearly
interim analyses are planned. Data capturing and corre-
sponding quality is monitored in the course of the obser-
vational trial.
ARR for patients treated with natalizumab during the
complete follow-up period (36 months) and those with
earlier discontinuation of natalizumab and subsequent al-
ternative MS treatment will be calculated. All endpoints
for patient-centric outcomes will be analyzed according to
the usual score calculations. Subgroup analyses according
to demographic variables, EDSS scores, relapse rates, bio-
marker status, MRI findings and natalizumab treatment
duration will be performed. AEs and data on safety-related
biomarkers captured in the daily practice routine will be
reported descriptively. Further explorative analysis and
subgroups will be defined in a statistical analysis plan prior
the database lock. Correlations of disease or treatment
characteristics to clinical parameters will be investigated
Ethical aspects
The study advisory committee advises on study design
and data analysis. An independent data monitoring com-
mittee is responsible for review of the ongoing safety of
patients enrolled in the study. TRUST has been ap-
proved by the responsible ethics committees at Heinrich
Heine University Düsseldorf (study number: 4675). Re-
gional ethics committees are consulted in accordance
with both the codex of the Voluntary Self-Regulation of the
Pharmaceutical Industry (FSA) [37] and recommendations
dealing with quality aspects of non-interventional observa-
tional studies issued by the German Federal Institute for
Drugs and Medical Devices (BfArM) [35]. Patients may
withdraw their consent to study participation at any time
without detrimental consequences for their further treat-
ment and care.
Publication
The results of the TRUST study will be published in agree-
ment with the study advisory committee and according to
the rules of the International Committee of Medical Journal
Editors and Good Publication Practice [38].
Discussion
Here we report on the study design of the prospective,
multicenter, non-interventional, long-term cohort study
TRUST. The study should improve the understanding of
the use and discontinuation of natalizumab in the routine
clinical practice setting, the influence of natalizumab on MS
disease course, the effectiveness of sustained natalizumab
treatment and the utility of risk-management and surveil-
lance tools as well as expert opinions in the real-life setting.
Currently, observations on the return of MS disease
activity after discontinuation of natalizumab have been
described in one prospective randomized clinical trial by
Fox et al [39]. Patients with stable disease status on
natalizumab therapy were randomized to continue nata-
lizumab treatment or switch to interferon beta, glatira-
mer acetate or corticosteroid treatment. The results
indicated increased MS disease activity after switching to
alternative treatments [39]. Further investigations in
similar settings, with treatment switched to fingolimod
or dimethyl fumarate, showed equal trends [26, 40]. To
date, the follow-up periods of these investigations have
been limited and information on the impact on disability
progression is lacking. The TRUST study allows for lon-
ger follow-up and investigation under real-life condi-
tions. Moreover, the utilization and the diagnostic and
predictive value of risk stratification approaches (anti-
JCV antibody serostatus and index as well as additional
non-validated biomarkers), as well as the use of MRI for
the early detection of PML, have not been assessed to date
in patients on long-term natalizumab treatment or in
those switching to other MS therapies in routine clinical
practice.
Due to the chronic course of MS disease with accumu-
lating disability and the need for long-term therapy, pa-
tients with MS generally require close medical attendance.
Close monitoring is required for patients receiving natali-
zumab to optimize their individual benefit-risk ratio [41].
Evaluating the impact of the JCV antibody index on treat-
ment decisions in this patient cohort in TRUST will be
informative with respect to benefit-risk considerations.
Furthermore, based on current PML risk estimates some
of the patients enrolled in TRUST may serve as an im-
portant control group for an assessment of disease activity
after 2 years of therapy.
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Interdisciplinary collaboration as well as expert con-
sultation are options commonly used in MS patient
management. This study therefore explores the use of
expert advice from experienced MS physicians to evalu-
ate its impact on treatment decisions.
The results of this study are expected to contribute to
the improvement of MS patient management and to fa-
cilitate rational treatment decisions in patients receiving
long-term therapy with natalizumab.
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